This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2001 Nov;45(5):775-83.

doi: 10.1067/mjd.2001.119085.

Intravenous immune globulin: fighting antibodies with antibodies

M V Dahl, A G Bridges

PMID: 11606935
DOI: 10.1067/mjd.2001.119085

Editorial

Intravenous immune globulin: fighting antibodies with antibodies

M V Dahl et al. J Am Acad Dermatol. 2001 Nov.

. 2001 Nov;45(5):775-83.

doi: 10.1067/mjd.2001.119085.

Authors

M V Dahl, A G Bridges

PMID: 11606935
DOI: 10.1067/mjd.2001.119085

No abstract available

PubMed Disclaimer

Comment on

Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR. Ahmed AR. J Am Acad Dermatol. 2001 Nov;45(5):679-90. doi: 10.1067/mjd.2001.116339. J Am Acad Dermatol. 2001. PMID: 11606916 Clinical Trial.

Similar articles

[Pemphigus--a model of modern dermatologic research].
Tappeiner J. Tappeiner J. Hautarzt. 1976 Apr;27(4):181-6. Hautarzt. 1976. PMID: 931747 German. No abstract available.
Design of randomized controlled trials.
Stanley K. Stanley K. Circulation. 2007 Mar 6;115(9):1164-9. doi: 10.1161/CIRCULATIONAHA.105.594945. Circulation. 2007. PMID: 17339574 Review. No abstract available.
IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it.
Bystryn JC, Rudolph JL. Bystryn JC, et al. J Invest Dermatol. 2005 Dec;125(6):1093-8. doi: 10.1111/j.0022-202X.2004.23930.x. J Invest Dermatol. 2005. PMID: 16354177 Review. No abstract available.
Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.
Green MG, Bystryn JC. Green MG, et al. Arch Dermatol. 2008 Dec;144(12):1621-4. doi: 10.1001/archdermatol.2008.503. Arch Dermatol. 2008. PMID: 19075146 Clinical Trial.
Standards of proof, standards of practice, and proof of standards: a tale of two trials.
Browman GP. Browman GP. J Clin Oncol. 2005 Apr 20;23(12):2583-5. doi: 10.1200/JCO.2005.11.910. Epub 2005 Feb 14. J Clin Oncol. 2005. PMID: 15710950 No abstract available.

See all similar articles

Cited by

Long-Term Follow-Up after Intravenous Immunoglobulin Therapy in Patients with Severe Ocular Mucous Membrane Pemphigoid Unresponsive to Conventional Therapy.
Leuci S, Amato M, Calabria E, Piscopo R, Tranfa F, Spagnuolo G, Mignogna MD. Leuci S, et al. J Ophthalmol. 2018 Sep 19;2018:8372146. doi: 10.1155/2018/8372146. eCollection 2018. J Ophthalmol. 2018. PMID: 30327726 Free PMC article.
High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.
Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. Ishii N, et al. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):186-95. doi: 10.1007/s12016-009-8153-y. Clin Rev Allergy Immunol. 2010. PMID: 19557317 Review.
Intravenous immunoglobulin in dermatology.
Dhar S. Dhar S. Indian J Dermatol. 2009;54(1):77-9. doi: 10.4103/0019-5154.48996. Indian J Dermatol. 2009. PMID: 20049279 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information